Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker RDHL · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Jul 31, 2025 | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia NCT04467840 · COVID-19, Lung Infection Opaganib, Placebo | RDHL RedHill Biopharma Limited | Phase 2/3 | Completed | 475 | Jul 18, 2021 | Registry ↗ |
| Jul 23, 2025 | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholang… NCT03377179 · Cholangiocarcinoma, Cholangiocarcinoma Non-resectable ABC294640, Hydroxychloroquine Sulfate 200 MG | RDHL RedHill Biopharma Limited | Phase 2 | Completed | 65 | Jun 21, 2022 | Registry ↗ |
| Mar 18, 2025 | RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease NCT04616924 · Pulmonary Mycobacterium Avium Complex Infection, Bronchiect… RHB-204, Placebo | RDHL RedHill Biopharma Limited | Phase 3 | Terminated | 12 | Aug 28, 2023 | Registry ↗ |
| Mar 18, 2025 | Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) NCT03414489 · Cholangiocarcinoma, Cholangiocarcinoma Non-resectable ABC294640 | RDHL RedHill Biopharma Limited | — | No longer available | — | — | Registry ↗ |
| Jun 6, 2024 | Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease NCT04723537 · Covid19 Part A: Upamostat 200 mg, Part A: Upamostat 400 mg | RDHL RedHill Biopharma Limited | Phase 2/3 | Terminated | 61 | Dec 28, 2021 | Registry ↗ |
| Jan 27, 2023 | Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Childr… NCT04027894 · Traveler's Diarrhea Rifamycin SV MMX, Placebo to Rifamycin SV-MMX | RDHL RedHill Biopharma Limited | Phase 2 | Unknown | 142 | Jan 2025 | Registry ↗ |
| Jan 27, 2023 | Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Childre… NCT04026984 · Traveler's Diarrhea Rifamycin SV-MMX, Placebo | RDHL RedHill Biopharma Limited | Phase 2 | Unknown | 142 | Jun 2025 | Registry ↗ |
| Mar 21, 2022 | A Study of Opaganib in Coronavirus Disease 2019 Pneumonia NCT04414618 · Coronavirus Infections Opaganib, Placebo | RDHL RedHill Biopharma Limited | Phase 2 | Completed | 42 | Nov 26, 2020 | Registry ↗ |
| Jun 18, 2021 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma NCT02757326 · Multiple Myeloma Opaganib | RDHL RedHill Biopharma Limited | Phase 1/2 | Terminated | 13 | May 2019 | Registry ↗ |
| Feb 24, 2021 | Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in A… NCT03009396 · Crohn Disease RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 m… | RDHL RedHill Biopharma Limited | Phase 3 | Completed | 54 | Nov 13, 2018 | Registry ↗ |
| Dec 8, 2020 | Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease NCT01951326 · Crohn's Disease RHB-104, Placebo | RDHL RedHill Biopharma Limited | Phase 3 | Completed | 331 | May 2018 | Registry ↗ |
| Aug 11, 2020 | Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen NCT04502069 · COVID-19, Lung Infection Opaganib | RDHL RedHill Biopharma Limited | Phase 1/2 | Withdrawn | 0 | Feb 2021 | Registry ↗ |
| Mar 16, 2020 | ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator NCT03198507 · Helicobacter Pylori Infection, Dyspepsia RHB-105, Active Comparator | RDHL RedHill Biopharma Limited | Phase 3 | Completed | 455 | Oct 24, 2018 | Registry ↗ |
| Jan 7, 2020 | ABC294640 in Treating Patients With Advanced Solid Tumors NCT01488513 · Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol… sphingosine kinase-2 inhibitor ABC294640 | RDHL RedHill Biopharma Limited | Phase 1 | Completed | 22 | Aug 2014 | Registry ↗ |
| Sep 24, 2019 | ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 NCT01980095 · Dyspepsia, Helicobacter Pylori Infection RHB-105, Placebo | RDHL RedHill Biopharma Limited | Phase 3 | Completed | 119 | Jun 2015 | Registry ↗ |
| Feb 20, 2019 | BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteri… NCT02246439 · Gastroenteritis, Gastritis RHB-102, Placebo Oral Tablet | RDHL RedHill Biopharma Limited | Phase 3 | Completed | 330 | Feb 13, 2017 | Registry ↗ |
| Aug 28, 2018 | Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Re… NCT02757105 · Irritable Bowel Syndrome With Diarrhea BEKINDA, Placebo | RDHL RedHill Biopharma Limited | Phase 2 | Completed | 127 | Jun 16, 2017 | Registry ↗ |
| Dec 7, 2017 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymph… NCT02229981 · Diffuse Large B Cell Lymphoma, Kaposi Sarcoma ABC294640 | RDHL RedHill Biopharma Limited | Phase 1/2 | Withdrawn | 0 | Jun 2019 | Registry ↗ |
| Jul 28, 2016 | Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Mu… NCT01717664 · Relapsing Remitting Multiple Sclerosis RHB-104 | RDHL RedHill Biopharma Limited | Phase 2 | Completed | 18 | Dec 2015 | Registry ↗ |
19 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 11:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances